Podcast episode 40 (in German)

Pentadeca Arginate (PDA): the successor to BPC-157 fact-checked

August 14, 2026

When the US authority FDA removed BPC-157 from compounding pharmacies at the end of 2023, a close relative moved up: Pentadeca Arginate. Same sequence, different salt, and precisely this small chemical difference kept the healing peptides in play in the US.

What it is about

PDA has the same sequence of 15 amino acids as BPC-157, a peptide originally isolated from a protective protein in human gastric juice. What differs is the salt partner: instead of an acetate, it comes with L-arginine, which is said to improve solubility and stability, even at room temperature. Arginine is also the raw material for nitric oxide, with which BPC-157 works anyway. The episode tells the regulatory history and explains the mechanisms from BPC-157 research and the 4 major areas of use: tendons and ligaments, joints and recovery after surgery, the intestinal barrier and regeneration in training. What remains is the contemporary form of a classic, resting on an unusually broad base of animal data.

Key points

Over decades, the group led by Predrag Sikirić in Zagreb has published hundreds of animal studies on BPC-157, from tendons, ligaments and muscles to the gastrointestinal tract and nerve tissue.
In 2009, Brcic and colleagues showed in the Journal of Physiology and Pharmacology that BPC-157 markedly accelerated the healing of severed tendons and muscles in an animal model.
A review by Seiwerth and colleagues summarized the state of research in Current Pharmaceutical Design in 2021: consistent healing signals across tissue types.
As mechanisms, the episode cites new vessel formation via the VEGF receptor 2 signaling pathway, activated fibroblasts for collagen formation and finely tuned blood flow via nitric oxide.
The basis of PDA lies in a 2013 patent; it only became known when BPC-157 was placed on the FDA’s Category 2 list at the end of 2023 and PDA was not.
As a report: US clinics describe faster perceived recovery, fewer complaints at tendon attachments and less conspicuous scars after surgery; there are no controlled studies on this.
In July 2026, an FDA advisory committee recommended putting BPC-157 on the 503A list, the route back into compounding pharmacies; that is not an approval.

Where the data stop

There are no randomized human studies of PDA itself, as of August 2026. That it works like BPC-157 is an inference from the chemistry: after dissolving, the salt dissociates, and the same sequence remains. The BPC-157 data themselves come predominantly from animal models, plus many reports of use from clinics, which do not replace a controlled study. Anyone selling PDA as “much stronger” than BPC-157 is exaggerating.

The reported side-effect profile is mild, for example a feeling of warmth or initially softer stools. Because the substance promotes vessel growth, it is considered off-limits in active tumor disease, as a precaution, not because of an observed problem. PDA is not approved as a medicine and is not permitted in competitive sport; the purity of gray-market products is a matter of trust. And a peptide does not replace physiotherapy.

Listen (in German)

Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music

Published on August 14, 2026.

The topic in the database

BPC-157 as an arginine salt: the same 15 amino acids, which became big when the FDA blocked BPC-157 for compounding pharmacies in 2023. Broad animal data on the sequence…Pentadeca Arginate (PDA)

All episodes in the app (German)

Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-09.